The Food and Drug Administration is accelerating the development of generic versions of complex biological drugs to increase competition and lower drug costs in the U.S. This move could impact pharmaceutical companies, as biosimilars are as safe and effective as branded products but cost significantly less, saving $20 billion in healthcare costs last year.
The FDA’s new reforms aim to cut the time it takes to bring a biosimilar to market in half, addressing the outdated and burdensome approval process. Biosimilars have historically struggled to gain market share compared to generic small-molecule drugs due to complex manufacturing and regulatory challenges.
Biological products account for 51% of total drug spending in the U.S., despite making up only 5% of prescriptions. Biosimilars, which are half the price of branded counterparts, have the potential to drive down drug prices by another 25%, providing relief for patients and promoting competition in the market.
The FDA proposed major updates to simplify biosimilar studies, recommending against requiring additional “switching studies” that can slow development and create confusion. The agency aims to streamline the approval process to increase the market share of biosimilars and provide more affordable options for patients.
Read more at CNBC
1. Apple announced a new iPhone 13 lineup with improved cameras and longer battery life. The new models will also feature a smaller notch and a more powerful A15 Bionic chip. Prices for the iPhone 13 will start at $699.
2. The Federal Reserve is expected to announce plans to begin tapering its bond-buying program in November. This move is in response to rising inflation rates and a recovering economy. The Fed will continue to monitor economic data before making a final decision.
3. The stock market saw a slight dip as investors expressed concerns over the Fed’s potential tapering plans. The S&P 500 and Dow Jones Industrial Average both experienced losses, while the Nasdaq Composite remained relatively flat. Tech stocks were particularly impacted by the news.: FDA to speed up generic drug approvals as Trump targets drug costs